Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.

Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, Harvey RD.

BMC Cancer. 2019 Aug 29;19(1):857. doi: 10.1186/s12885-019-6073-7.


Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.

Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA.

Invest New Drugs. 2019 Feb 6. doi: 10.1007/s10637-019-00736-0. [Epub ahead of print]


The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.

Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD.

Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17.


The addition of chemotherapy in the definitive management of high risk prostate cancer.

Ferris MJ, Liu Y, Ao J, Zhong J, Abugideiri M, Gillespie TW, Carthon BC, Bilen MA, Kucuk O, Jani AB.

Urol Oncol. 2018 Nov;36(11):475-487. doi: 10.1016/j.urolonc.2018.07.020. Epub 2018 Oct 9. Review.


Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.

Owonikoko TK, Busari AK, Kim S, Chen Z, Akintayo A, Lewis C, Carthon BC, Alese OB, El-Rayes BF, Ramalingam SS, Harvey RD.

Oncology. 2018;95(3):138-146. doi: 10.1159/000488763. Epub 2018 Jun 18.


Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.

Bilen MA, Dutcher GMA, Liu Y, Ravindranathan D, Kissick HT, Carthon BC, Kucuk O, Harris WB, Master VA.

Clin Genitourin Cancer. 2018 Jun;16(3):e563-e575. doi: 10.1016/j.clgc.2017.12.015. Epub 2018 Jan 4.


A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma.

Sekar RR, Patil D, Baum Y, Pearl J, Bausum A, Bilen MA, Kucuk O, Harris WB, Carthon BC, Alemozaffar M, Filson CP, Pattaras JG, Nieh PT, Ogan K, Master VA.

Asian J Urol. 2017 Oct;4(4):230-238. doi: 10.1016/j.ajur.2017.04.002. Epub 2017 May 10.


Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma.

Harris WB, Zhang C, Liu Y, Robertson DK, Akbashev MY, Lingerfelt BM, Kucuk O, Carthon BC, Gillespie TW, Osunkoya AO, Master VA.

Tumour Biol. 2017 Jun;39(6):1010428317705514. doi: 10.1177/1010428317705514.


Clinical Considerations and Challenges in Treating Patients With Oligometastatic Prostate Cancer.

Carthon BC.

J Oncol Pract. 2017 Jan;13(1):19-20. doi: 10.1200/JOP.2016.018838. Epub 2017 Jan 3. No abstract available.


The STAMPEDE trial: paradigm-changing data through innovative trial design.

Carthon BC, Antonarakis ES.

Transl Cancer Res. 2016 Sep;5(3 Suppl):S485-S490.


Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.

DeFilipp Z, Rosand CB, Goldstein DA, Master VA, Carthon BC, Harris WB, Kucuk O, Al-Kadhimi Z, Cohen JB, Flowers CR, Lechowicz MJ, Nooka AK, Kaufman JL, Langston AA, Chen Z, Arora J, Waller EK.

Bone Marrow Transplant. 2017 Jan;52(1):132-134. doi: 10.1038/bmt.2016.189. Epub 2016 Jul 18. No abstract available.


Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases.

Fatima N, Canter DJ, Carthon BC, Kucuk O, Master VA, Nieh PT, Ogan K, Osunkoya AO.

Can J Urol. 2015 Jun;22(3):7783-7.


Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.

Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, Ahmed R, Khan MK.

Neuro Oncol. 2015 Oct;17(10):1312-21. doi: 10.1093/neuonc/nov093. Epub 2015 May 25. Review.


Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma.

Hsiao W, Herrel LA, Yu C, Kattan MW, Canter DJ, Carthon BC, Ogan K, Master VA.

Int J Urol. 2015 Mar;22(3):264-70. doi: 10.1111/iju.12672. Epub 2014 Nov 26.


Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.

Carthon BC, Ng CS, Pettaway CA, Pagliaro LC.

BJU Int. 2014 Jun;113(6):871-7. doi: 10.1111/bju.12450.


Therapeutic options for a rising PSA after radical prostatectomy.

Carthon BC, Marcus DM, Herrel LA, Jani AB, Rossi PJ, Canter DJ.

Can J Urol. 2013 Jun;20(3):6748-55. Review.


Salvage therapy for locally recurrent prostate cancer after radiation.

Marcus DM, Canter DJ, Jani AB, Dobbs RW, Schuster DM, Carthon BC, Rossi PJ.

Can J Urol. 2012 Dec;19(6):6534-41. Review.


Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P.

Clin Cancer Res. 2010 May 15;16(10):2861-71. doi: 10.1158/1078-0432.CCR-10-0569. Epub 2010 May 11.


Genetic replacement of cyclin D1 function in mouse development by cyclin D2.

Carthon BC, Neumann CA, Das M, Pawlyk B, Li T, Geng Y, Sicinski P.

Mol Cell Biol. 2005 Feb;25(3):1081-8.

Supplemental Content

Loading ...
Support Center